Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REP 2139-Mg
- Development stage
- Phase 2
- Lead developer
- Replicor
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous, Intravenous
01
Overview
REP 2139-Mg is a magnesium chelate formulation of the nucleic acid polymer (NAP) drug candidate known as REP 2139. It is an antiviral oligonucleotide designed to inhibit the release of hepatitis B surface antigen (HBsAg), thereby restoring immune control over hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The drug acts as a direct-acting agent against HDV replication and subviral particle assembly. Clinical studies have shown that it can lead to rapid normalization of liver enzymes, clearance or significant reduction in HBsAg and HDV RNA levels, seroconversion to anti-HBs status, and reversal of liver decompensation even in patients with advanced cirrhosis or those who failed previous therapies such as bulevirtide or pegylated interferon. Subcutaneous administration has demonstrated improved efficacy compared to intravenous infusion. The drug is being developed by Replicor for use in chronic HBV infection—including HBV/HDV co-infection—and has been tested both as monotherapy and in combination with tenofovir disoproxil fumarate (TDF) and pegylated interferon alfa-2a[2][3][4][5][8].
- Other names
- nucleic acid polymer REP 2139NAP REP 2139
02
Targets
HBsAg (Hepatitis B surface antigen)HDAg (Hepatitis delta antigen)
Beyond the preview
Go deeper on REP 2139-Mg.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REP 2139-Mg.